Navigation Links
Hemodialysis Patient Share for Sanofi's Ferrlecit Increased Significantly in the First Quarter of 2013 Compared to the Previous Quarter
Date:4/15/2013

EXTON, Pa., April 15, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that in hemodialysis (HD), Sanofi's Ferrlecit patient share has experienced a significant 9 percent increase between Q4 2012 and Q1 2013. In Chronic Kidney Disease Non-Dialysis (CKD-ND), patient share for American Regent's Venofer has increased significantly since this period last year (at the expense of Ferrlecit and AMAG Pharmaceuticals' Feraheme), although the percent of patients on IV iron in this patient population is considerably lower than in the HD population.   

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36805LOGO)

The TreatmentTrends®: Nephrology (U.S.) report, in which 200 U.S. based nephrologists were surveyed, also finds that—in regard to bone and mineral metabolism—reported phosphate binder use declined in every late stage CKD and dialysis patient population, significantly in HD and peritoneal dialysis, compared to Q4 2012. The report also notes a decline of phosphate binder use over longer time periods.

"There may be several reasons why phosphate binder use appears to be declining over time, including influence of dialysis bundling, cost containment pressures for the facility and more expensive patient co-pays," said BioTrends Research Group Director of Nephrology Rob Dubman . "Another theory is less use of combination binder therapy—in fact, while reported combination use has remained fairly consistent in CKD-ND, the TreatmentTrends Nephrology report series has found a significant decline of binder combination therapy in the dialysis population over time."

The first quarter of 2013 was also marked with clinical advances for Keryx Biopharmaceuticals' Zerenex, Rockwell Medical's SFP and Vifor Pharma's PA21. Despite these clinical advances, surveyed nephrologists' familiarity with these products is generally low, but interest is moderate to high after respondents reviewed a brief product description. The report provides further details regarding the percent of patients likely to be candidates for these products and likely products to be replaced by the new iron-based binders.

TreatmentTrends®: Nephrology (U.S.) is a syndicated quarterly report series, based on primary market research that provides a comprehensive view of the current and expected future management of renal anemia and bone and mineral metabolism in patients with chronic kidney disease. Topics include percent of patients on each therapy, patient share, therapy initiation levels, perception of current laboratory values, attribute importance and performance ratings, bundling, compliance, statement agreements, reaction to new products in development, among other topics. The Q1 2013 wave published in March 2013 and the Q2 2013 wave will publish in June 2013. Survey instrument is available upon request.

Webinar
Media members are welcome to attend our upcoming webinar entitled Renal Anemia in Chronic Kidney Disease (CKD): Following the Omontys Recall. This webinar will be held on April 25 at 10 AM EST and on April 30 at 2 PM EST. To learn more and to register, click here.

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at www.bio-trends.com.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresources.com


'/>"/>
SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cantel Medicals Mar Cor Purification Subsidiary Acquires Hemodialysis Water Business from Siemens Water Technologies Business Unit
2. Home Hemodialysis Patients Urge Medicare to Fix HHD Training Reimbursement
3. NxStage Announces CE Mark Approval for Nocturnal Home Hemodialysis
4. NxStage Initiates 2013 Call to Action Campaign with Launch of Hemodialysis At Home: A Better Way For a Better Life
5. NxStage Home Hemodialysis Patient Awareness Tour Kicks Off January 29th
6. NxStage Submits Formal Comments to CMS to Improve Patient Access to Life-changing More Frequent Home Hemodialysis Therapy
7. Renal Dialysis Equipment Market to 2017- Lower Costs and Similar Efficacy Rates as Hemodialysis to Increase Adoption Rates of Peritoneal Dialysis
8. FREEDOM Study Data: Patients Experience Sustained Quality of Life Benefits with More Frequent Home Hemodialysis with the NxStage System One
9. Study Shows NxStage Daily Home Hemodialysis Patients More Likely to Receive Kidney Transplant
10. Sorbent Therapeutics Initiates Phase 2b Clinical Trial of CLP-1001 for Treatment of Signs and Symptoms of Fluid Overload in Patients with Heart Failure
11. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2019)... ... September 17, 2019 , ... Called Muss-Bits (Musical Sensory Substitution Bits) it ... Design Awards Students category. , It was developed by Associate Professor Suranga Nanayakkara and ... is comprised of two parts. A “sensor bit” that can be placed on or ...
(Date:9/17/2019)... ... September 17, 2019 , ... ... to establish a new partnership with NextGen Healthcare Inc., a leading healthcare solutions ... partners, which include Nextech, DrChrono, Symplast and Azalea, with additional partnerships to announce ...
(Date:9/17/2019)... CHERRY HILL, N.J. (PRWEB) , ... September 17, ... ... of Canal Calem Periodontics located in Moorestown and Medford, NJ, now welcome patients ... team of periodontists strives to save natural teeth whenever possible. When tooth removal ...
Breaking Medicine Technology:
(Date:9/11/2019)... , ... September 11, 2019 , ... ... exhibit at the 2019 AHIMA Health Data and Information Conference in Chicago, Illinois ... by booth #505 to learn more about GRM’s healthcare information management solutions ...
(Date:9/11/2019)... ... September 11, 2019 , ... Autopsies don’t lie. ... injury to the body. , Methamphetamine permanently harms the heart. It increases risks ... getting a better understanding of how the damage occurs. , An August ...
(Date:9/11/2019)... ... 2019 , ... Ahipoki is excited to announce a new vegan and gluten ... vegetarians, pescatarians and poke bowl fans alike. Ahimi is made of five simple ... texture similar to tuna, Ahipoki customers will now have a vegan option ...
(Date:9/11/2019)... ... ... Women’s Excellence is excited to announce the opening of their new Royal ... Royal Oak, MI 48073 in the heart of Royal Oak off Woodward Avenue south ... a contemporary, spa-like atmosphere. We are thrilled to be in a great, central ...
(Date:9/11/2019)... , ... September 10, 2019 , ... ... Doctors by Pasadena Magazine. These physicians have been recognized among the best doctors ... pediatric subspecialties:, Robert H. Cho, M.D. – Chief ...
Breaking Medicine News(10 mins):